sintilimab + nivolumab + camrelizumab

**Sintilimab + nivolumab + camrelizumab** denotes three separate anti-programmed cell death protein 1 monoclonal antibodies rather than a verified co-formulated medicine or established three-antibody regimen. Each constituent blocks programmed cell death protein 1 signaling to prevent inhibitory ligand engagement and restore antitumor T-cell activity. Public-source occurrences that list these three agents together describe them as alternative immune-checkpoint inhibitors used across patients or within a generic intervention category, rather than evidence that all three were administered concurrently as one therapeutic regimen. ([link.springer.com](https://link.springer.com/content/pdf/10.1007/s40278-024-61112-3.pdf))